News
DNA
8.41
+4.08%
0.33
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
Benzinga · 05/18 15:25
Weekly Report: what happened at DNA last week (0511-0515)?
Weekly Report · 05/18 09:35
Ginkgo Bioworks: Another Lost Year
Seeking Alpha · 05/13 14:44
Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Simply Wall St · 05/13 11:37
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
TipRanks · 05/11 15:50
Weekly Report: what happened at DNA last week (0504-0508)?
Weekly Report · 05/11 09:34
Ginkgo Bioworks Earnings Call: Cash Rich, Revenue Pinched
TipRanks · 05/10 00:03
Ginkgo Bioworks Holdings (DNA) TTM Net Loss Of US$312.8 Million Reinforces Bearish Narratives
Simply Wall St · 05/09 03:47
Ginkgo Bioworks (DNA) Q1 2026 Earnings Transcript
The Motley Fool · 05/08 20:11
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M
Seeking Alpha · 05/08 16:23
Ginkgo Bioworks Reaffirmed at Buy as Strategic Refocus, Cost Cuts and New Partnerships Support Unchanged $12 Price Target
TipRanks · 05/08 04:05
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks
Seeking Alpha · 05/08 03:33
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
TipRanks · 05/07 20:55
*Ginkgo Bioworks Holdings 1Q Basic Loss/Shr $1.39 >DNA
Dow Jones · 05/07 20:47
*Ginkgo Bioworks Presenting Results of Ops for Former Business Within Discontinued Ops >DNA
Dow Jones · 05/07 20:45
*Ginkgo Bioworks Previously Reported Fincl Results for Comparable Periods Retrospectively Recast >DNA
Dow Jones · 05/07 20:45
*Ginkgo Bioworks Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Dow Jones · 05/07 20:44
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
PR Newswire · 05/07 20:05
Press Release: Ginkgo Bioworks Reports First -2-
Dow Jones · 05/07 20:05
Weekly Report: what happened at DNA last week (0427-0501)?
Weekly Report · 05/04 09:33
More
Webull provides a variety of real-time DNA stock news. You can receive the latest news about Ginkgo Bioworks Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.